Changeflow GovPing Pharma & Drug Safety US12600990B2 - mRNA Induced Expression of BMP a...
Routine Notice Added Final

US12600990B2 - mRNA Induced Expression of BMP and Receptor and Methods Related Thereto

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted patent US12600990B2 to inventors Alexander Day and Bradford Mullin covering methods of preparing synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptor in lipid-solubilized carriers for intraoperative delivery to bone fusion beds. The patent includes 20 claims and covers CPC classifications including C12N 15/88, A61K 47/543, A61K 48/0041, and C07K 14/51.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12600990B2, covering methods for preparing synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptors delivered via lipid carriers. The claims encompass intraoperative bone harvest samples incubated with lipid-solubilized mRNA to form activated BMP material for delivery to bone fusion beds.

Biotechnology and pharmaceutical companies developing mRNA-based therapeutics or bone fusion treatments should review this patent to assess freedom-to-operate implications for related product development. Patent grants are informational publications and do not impose compliance obligations on non-parties.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

MRNA induced expression of bone morphogenic protein and receptor and methods related thereto

Grant US12600990B2 Kind: B2 Apr 14, 2026

Inventors

Alexander Day, Bradford Mullin

Abstract

Methods and treatments including preparing a synthetic messenger ribonucleic acid (mRNA) encoding at least for a bone morphogenic protein (BMP) and/or a BMP receptor. The synthetic mRNA is lipid-solubilized in a lipid or lipid derivative carrier. Intraoperatively, a bone harvest sample is obtained and incubated with the lipid-solubilized mRNA. The bone harvest sample internalizes at least a portion of the lipid-solubilized mRNA, thereby forming activated BMP and/or BMPR material. The activated BMP and/or BMPR material may be delivered intraoperatively to a bone fusion bed.

CPC Classifications

C12N 15/88 A61K 47/543 A61K 48/0041 C07K 14/51

Filing Date

2022-10-03

Application No.

18246062

Claims

20

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600990B2

Who this affects

Applies to
Drug manufacturers Manufacturers
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Patent grant mRNA therapeutics Bone fusion methods
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!